AmacaThera, a clinical-stage biotechnology company specializing in drug delivery, has announced a new pipeline program in collaboration with a leading global pharmaceutical company. Through this partnership, a single-injection, long-acting biologic will be developed using AmacaThera’s advanced hydrogel delivery platform, AmacaGel, in combination with the partner’s therapeutic. Co-funded by both organizations, the initiative will leverage their complementary strengths and resources...